Mabwell (Shanghai) Bioscience Co., Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Maiwei (Shanghai) Biotechnology Co., Ltd. (688062. SH) is an innovative biopharmaceutical company with a full industry chain layout. It always adheres to the vision of "turning innovation from dreams into reality", and implements the mission of "exploring life and benefiting health". Through innovation at the source, it provides patients with better therapeutic effects and stronger accessibility of biopharmaceutical drugs, meeting the unmet clinical needs of the world. Maiwei Biotechnology has built an innovative system that starts with the discovery of antibody drug targets and molecules, covering the entire drug research and development cycle, including drug resistance research, preclinical research, clinical research, and production transformation. It has achieved a comprehensive industrial chain layout that integrates research and development, production, and marketing. We focus on the treatment fields of autoimmune, tumor, metabolism, ophthalmology, infection, and other fields. With our internationally leading five characteristic technology platforms and R&D innovation capabilities, we have established rich and competitive pipelines. There is currently 1 product on the market, and 15 varieties under research are in different research and development stages, including 12 innovative varieties and 3 biologically similar drugs. Among them, 2 varieties have submitted marketing applications, and 3 varieties are in the critical registration clinical trial stage. And independently undertake one major national science and technology special project for "major new drug development", two national key research and development plans, and multiple provincial and municipal level science and technology innovation projects. Maiwei Biotechnology focuses on innovation and industrial transformation. The antibody and recombinant protein drug industrialization base that meets the standards of China's NMPA, US FDA, and EU EMAGMP has been put into use in Taizhou, Jiangsu, and has passed the EU QP audit. A large-scale commercial production base located in Shanghai is currently under construction. |
| Headquarter | Shanghai |
| Establish Date | 5/12/2017 |
| Listed Code | 688062.SH |
| Listed Date | 1/18/2022 |
| Chairman | Liu Datao. |
| CEO | Liu Datao. |
| Website | mabwell.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
